Evaluated the use of CAR T-cells co-expressing interleukin-15 (IL-15) and interleukin-21 (IL-21) in a patient with hepatoblastoma, assessing tumor response to this novel cellular therapy.
Complete regression of hepatoblastoma was achieved following treatment with IL-15– and IL-21–coexpressing CAR T-cells.
Published as a case communication (letter), limiting generalizability; single patient report with no control comparator; long-term durability of response and safety profile not yet established.
IL-15 and IL-21 co-expression in CAR T-cells may meaningfully enhance antitumor activity in pediatric hepatoblastoma. This early signal warrants follow-up in prospective trials before broader clinical adoption.